Foot Locker

(Z) - Get Report

, formerly Venator and before that Woolworth, reported third-quarter earnings, before items, of 26 cents a share, meeting analysts' estimates. Sales totaled $1.08 billion. Same-store sales rose 5.6%. The company projected earnings of 25 cents to 30 cents a share for the fourth quarter and income of 95 cents to $1 a share for the year. Analysts expect earnings of 30 cents in the quarter and $1 for the year.

Earnings Reports & Warnings

Big Lots

(BLI)

reported a loss of 14 cents a share for the third quarter, missing estimates by a penny. Sales rose 5.4% to $773.1 million. Comparable-store sales for stores open two years at the beginning of the fiscal year were flat for the quarter. The closeout retailer estimated that fourth-quarter earnings will be in the range of 50 cents a share, while analysts are looking for income of 55 cents.

Brookstone

(BKST)

posted a third-quarter loss of $1.07 a share. Third-quarter sales fell 8.3% to $58.5 million, and same-store sales dropped 17% from last year.

CBRL Group

(CBRL) - Get Report

earned 35 cents a share in the latest first fiscal quarter, matching Wall Street's estimates. The restaurant group said revenue rose 6% to $495.2 million. For the second quarter, the company expects earnings to grow at least 15% from the same period a year ago, when CBRL brought in 26 cents a share. That guidance would imply income of about 30 cents a share, which would be a penny shy of estimates, according to First Call.

Dillard's

(DDS) - Get Report

lost 48 cents a share in the third fiscal quarter. Analysts were calling for a loss of 42 cents. The department store owner said sales for the quarter fell 5% to $1.87 billion. Same-store sales decreased 6%.

Miscellaneous News

Chiron

(CHIR) - Get Report

reported disappointing results from a Phase III trial evaluating tifacogin in severe sepsis. The results from the trial indicate that tifacogin didn't meet the primary goal of reducing 28-day mortality. The company said there weren't any safety issues identified in the patients who took the treatment. Tifacogin is being developed by Chiron and

Pharmacia

(PHA)

.

Analyst Actions

Salomon Smith Barney downgraded

Microsoft

(MSFT) - Get Report

to neutral from outperform based on the stock's valuation. The firm said the shares are trading at the high end of the historical price-to-earnings and price-to-sales ranges, despite declining margins and a lower growth rate. Salomon also said estimates for the March and June quarters might be too aggressive because of weakness in Japan and Europe.

After Tuesday's Close

Amgen

(AMGN) - Get Report

provided Wall Street with an optimistic forecast for 2002. The company said it expects earnings per share to grow in the low-20% range in 2002. Analysts are expecting the company to post earnings of $1.19 a share this year and $1.40 in 2002. Earnings growth of even 20% implies a bottom line of about $1.43 for next year. The forecast excludes the effects of a possible new application for Aranesp and pegfilgrastim, a long-acting version of Neupogen.

Analog Devices

(ADI) - Get Report

topped fourth-quarter estimates, but guided Wall Street lower. The company posted fourth-quarter earnings of 14 cents a share, 2 cents ahead of estimates. Revenue totaled $423 million, but the company expects the top line to drop 5% in the first fiscal quarter. Analog also projected earnings of 11 cents a share for the quarter, while analysts are looking for 15 cents.

Triquint Semiconductor

(TQNT)

forecast fourth-quarter revenue at the low end of its previous $75 million to $80 million range. The chipmaker also said it expects to earn 4 cents a share in the quarter, in line with analysts' estimates, although at the low end of its own previously issued guidance. The estimate excludes an expected $100 million charge related to excess capacity.